XERS XP-8121 targets $1-3B hypothyroidism market with 2030 launch
XP-8121 for hypothyroidism is positioned as a once-weekly subcutaneous therapy backed by a clinical program and strong physician interest, with a targeted 2030 launch supported by regulatory alignment and IP.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.